概括
2022年的一项调查显示,只有25%的多发性骨髓瘤患者因制造问题而接受CAR T细胞治疗. 提高细胞生产和测试可以增加可用性,满足潜在的未来需求.
科学领域:
- 在瘤学瘤学.
- 细胞疗法细胞疗法
- 生物制造 生物制造 生物制造
背景情况:
- 卡尔T细胞疗法是治疗多发性骨髓瘤的一个有希望的疗法.
- 患者获得CAR T细胞疗法受到制造能力的限制.
- 2022年的一项调查突出显示,有显著的治疗差距.
研究的目的:
- 评估当前对多发性骨髓瘤患者的CAR T细胞治疗的可获得性.
- 确定限制CAR T细胞疗法生产和输送的关键因素.
- 根据潜在的处理扩张,预测未来的需求.
主要方法:
- 对2022年患者调查数据的分析.
- 识别制造瓶,包括病毒载体供应.
- 评估新制造和测试方法的潜在影响.
主要成果:
- 只有大约25%的多发性骨髓瘤患者接受了CAR T细胞治疗.
- 制造业的瓶,特别是病毒载体的短缺,被确定为主要限制.
- 如果CAR T细胞疗法被批准用于早期治疗阶段,可能会增加需求.
结论:
- 目前的CAR T细胞治疗制造能力不足以满足患者的需求.
- 细胞制造和测试方面的创新对于改善患者接入至关重要.
- 预测和解决未来的需求对于广泛采用CAR T细胞疗法至关重要.
相关概念视频
01:22T Cell Activation and Clonal Selection
774
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
774
01:27Tumor Immunotherapy
539
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539